Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-centre, Open-label, Phase IV, Interventional Study to Evaluate the Efficacy of Erlotinib (Tarceva®) Following 4 Cycles of Platinum-based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Not Experienced Disease Progression or Unacceptable Toxicity During Chemotherapy

NCT01230710 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT01230710
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01230710 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-centre, Open-label, Phase IV, Interventional Study to Evaluate the Efficacy of Erlotinib (Tarceva®) Following 4 Cycles of Platinum-based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Not Experienced Disease Progression or Unacceptable Toxicity During Chemotherapy
Lead sponsor
Hoffmann-La Roche
Phase
Phase 4
Overall status
Completed
Start date
March 31, 2011
Completion date
September 30, 2013
Enrollment
51 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer